3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
43
Nivolumab
29
atezolizumab
11
Specimen Handling
10
Cyclophosphamide
10
Bevacizumab
10
Paclitaxel
9
Magnetic Resonance Spectroscopy
9
cabozantinib
7
Ipilimumab
7
Carboplatin
7
fludarabine
6
durvalumab
6
avelumab
6
Sunitinib
6
Sorafenib
6
Oxaliplatin
6
Fluorouracil
6
Docetaxel
6
spartalizumab
5
sargramostim
5
Leucovorin
5
Cisplatin
5
Cetuximab
5
aldesleukin
4
Trastuzumab
4
Radiosurgery
4
Psychiatric Rehabilitation
4
Irinotecan
4
Gemcitabine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
Blood Component Removal
×
Gastrointestinal
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled